Vfend

Histoplasmosis, Candidemia, Coccidioidomycosis + 24 more

Treatment

13 FDA approvals

20 Active Studies for Vfend

What is Vfend

Voriconazole

The Generic name of this drug

Treatment Summary

Ethanol is a type of alcohol that is rapidly absorbed from the stomach and distributed around the body. It has powerful germ-killing properties, so it is often used as a disinfectant. It also has other uses in medicines and as the main ingredient in alcoholic drinks.

Voriconazole

is the brand name

image of different drug pills on a surface

Vfend Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Voriconazole

Voriconazole

2002

85

Approved as Treatment by the FDA

Voriconazole, also known as Voriconazole, is approved by the FDA for 13 uses like Esophageal Candidiasis and Scedosporium Infection .

Esophageal Candidiasis

Scedosporium Infection

Systemic candidiasis

refractory Fungal Infections

Invasive Aspergillosis

Hematopoietic stem cells

Neutropenia

Neuroaspergillosis

Candida (fungus)

prophylaxis of moderate Pneumocystis pneumonia

Candidemia

Fusariosis

Mycoses

Effectiveness

How Vfend Affects Patients

Alcohol can damage cells by drying them out and breaking down their inner structures. This is why it can kill bacteria and fungi. When alcohol comes in contact with nerve tissue, it can cause inflammation and damage to the nerves. Most of the ethanol that enters the body is broken down and oxidized. It is also used in small amounts to dissolve medicines and create a mild sedative effect in some drugs. Ethanol also binds to certain receptors in the body, like GABA and glycine, and affects how they work. The body also breaks down ethanol using a special enzyme in the liver called alcohol dehydrogenase.

How Vfend works in the body

Ethanol affects the brain by changing the structure and activity of neurons. It binds directly to receptors for acetylcholine, serotonin, GABA, and glutamate. Ethanol also has calming effects by binding to GABA and glycine receptors. It can also act as an anti-infective by disrupting the balance of fluids across cell membranes.

When to interrupt dosage

The encouraged measure of Vfend is dependent upon the diagnosed condition, including Urinary Tract Infection (UTI), Hand Hygiene and ethylene glycol. The quantity of dosage fluctuates, in line with the administration technique (e.g. Topical or Solution, gel forming / drops) provided in the following table.

Condition

Dosage

Administration

talaromycosis

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal

Aspergillosis

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal

Meningitis, Fungal

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal

Aspergillosis

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal

prophylaxis of moderate Pneumocystis pneumonia

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal

Peritonitis

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal

Debridement

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal

Lung Transplant

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal

Hematopoietic stem cells

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal

Candidemia

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal

Fusariosis

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal

Aspergillosis

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal

Histoplasmosis

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal

Coccidioidomycosis

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal

Neutropenia

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal

Immunosuppression

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal

Esophageal Candidiasis

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal

Yeast Infection

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal

Candida (fungus)

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal

aspergillus endophthalmitis

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Intravenous, Powder, for suspension - Oral, Powder, for suspension, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension - Oral, Suspension, Tablet, coated - Oral, Tablet, coated, Powder - Intravenous, Powder, Tablet, film coated - Nasal, Nasal

Warnings

Vfend Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Voriconazole may interact with Pulse Frequency

There are 20 known major drug interactions with Vfend.

Common Vfend Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Major

The metabolism of (R)-warfarin can be decreased when combined with Voriconazole.

(S)-Warfarin

Major

The metabolism of (S)-Warfarin can be decreased when combined with Voriconazole.

1,2-Benzodiazepine

Major

The metabolism of 1,2-Benzodiazepine can be decreased when combined with Voriconazole.

3,5-diiodothyropropionic acid

Major

The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Voriconazole.

5-androstenedione

Major

The metabolism of 5-androstenedione can be decreased when combined with Voriconazole.

Vfend Toxicity & Overdose Risk

The lowest toxic dose of this drug in rats has been found to be 5628mg/kg. Overdosing on this drug can cause nausea, vomiting, reduced brain activity, respiratory failure, or death. Those who take this drug over a long period of time may also experience severe health problems such as liver or brain damage.

image of a doctor in a lab doing drug, clinical research

Vfend Novel Uses: Which Conditions Have a Clinical Trial Featuring Vfend?

32 active clinical trials are presently assessing the potential of Vfend in providing relief from Obstructive Hypertrophic Cardiomyopathy, Urinary Tract Infection (UTI) and Disinfection.

Condition

Clinical Trials

Trial Phases

talaromycosis

0 Actively Recruiting

Esophageal Candidiasis

0 Actively Recruiting

Osteomyelitis

0 Actively Recruiting

Fusariosis

0 Actively Recruiting

Neutropenia

4 Actively Recruiting

Phase 1, Phase 2, Phase 3

Immunosuppression

10 Actively Recruiting

Phase 2, Phase 4, Not Applicable, Phase 3, Early Phase 1

Aspergillosis

0 Actively Recruiting

Candida (fungus)

0 Actively Recruiting

Histoplasmosis

1 Actively Recruiting

Phase 3

Mycoses

0 Actively Recruiting

Aspergillosis

0 Actively Recruiting

Neuroaspergillosis

0 Actively Recruiting

refractory Oral Candidiasis

0 Actively Recruiting

Lung Transplant

17 Actively Recruiting

Not Applicable, Phase 2, Phase 3, Phase 1

Candidemia

3 Actively Recruiting

Phase 3, Phase 2

Peritonitis

0 Actively Recruiting

Meningitis, Fungal

0 Actively Recruiting

Debridement

0 Actively Recruiting

Yeast Infection

0 Actively Recruiting

Valve Replacement

0 Actively Recruiting

Vfend Reviews: What are patients saying about Vfend?

4.7

Patient Review

2/15/2008

Vfend for Aggressive Fungal Infection - Invasive Aspergillosis

I used this after Diflucan for Coccidioidomyhcosis (Valley Fever). Unfortunately, I had severe vomiting, hallucinations, and woke up in middle of night to searing pain in foot then numbness on that entire side of body. This was after 3 - 200mg doses.

4.7

Patient Review

3/30/2011

Vfend for Candidiasis Yeast Infection that Spreads Throughout Body

I've been struggling with chronic candidiasis for over a decade now, and this is the first medication I've tried that's actually been effective at killing it.

4.3

Patient Review

12/29/2007

Vfend for Aggressive Fungal Infection - Invasive Aspergillosis

4

Patient Review

12/10/2010

Vfend for Aggressive Fungal Infection - Invasive Aspergillosis

I found that taking two pills a day led to an increase in my blurry vision and dizziness. These side effects were amplified when I used antibiotics alongside the medication. After a couple months, I went down to one pill per day and experienced minimal side effects. However, upon stopping the treatment altogether, my aspergillosis came back relatively quickly.

3.7

Patient Review

12/27/2013

Vfend for Aggressive Fungal Infection - Invasive Aspergillosis

The biggest issue I've had is loss of appetite; I went back on a feeding tube five months after my double lung transplant. This medication saps all my energy and makes my stomach churn constantly, but it's working. I'm doing 200mg twice a day.

3.7

Patient Review

2/3/2008

Vfend for Aggressive Fungal Infection - Invasive Aspergillosis

3.7

Patient Review

8/10/2009

Vfend for Aggressive Fungal Infection - Invasive Aspergillosis

I have skin cancer and it keeps coming back as squamous cell carcinomas. I've had a lot of the listed side effects from this medication, but my transplant doctor put me on it as a precautionary measure in 2004.

2.3

Patient Review

10/12/2008

Vfend for Aggressive Fungal Infection - Invasive Aspergillosis

Nausea and blurred vision were my initial side effects when starting this medication; however, they have since subsided. I've been on the drug for 2 1/2 years now and it's kept me alive without any negative impact on my transplant.

2.3

Patient Review

4/25/2021

Vfend for Aggressive Fungal Infection - Invasive Aspergillosis

VFend was honestly just too tough for me to handle long-term. The side effects were really bad and even after I stopped taking it, I felt the consequences for months afterwards. If my infection comes back...I don't know what I'll do, but this medication is not an option for me anymore.

1.7

Patient Review

3/22/2012

Vfend for Aggressive Fungal Infection - Invasive Aspergillosis

I have aspergillus and was treated with IV Vfend before and after a double lung transplant. I experienced terrifying hallucinations for days both times, although docs suspected the pain medication was potentiating this effect. I am getting ready to start again, 200mg twice daily oral, and I am not looking forward to it. The drug is horrible but sadly there are few options.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about vfend

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is VFEND an antibiotic?

"Vfend is an antifungal medicine used to treat infections caused by yeast or other types of fungus."

Answered by AI

What is the generic name for VFEND?

"This is the oral form of voriconazole, a drug used to treat certain types of fungal infections.

This drug is used to treat certain types of fungal infections. It is available in an oral form."

Answered by AI

What is voriconazole used to treat?

"Voriconazole is used to treat serious fungal or yeast infections, such as aspergillosis (fungal infection in the lungs), candidemia (fungal infection in the blood), esophageal candidiasis (candida esophagitis), or other fungal infections (infections in the skin, stomach, kidney, bladder, or wounds)."

Answered by AI

How long can I take voriconazole?

"The usual length of treatment with Vfend (voriconazole) is at least 2 weeks, but this may be longer or shorter depending on the severity of the infection. In some cases, treatment may last for several months."

Answered by AI

Clinical Trials for Vfend

Image of University of Minnesota in Minneapolis, United States.

LAmB and Posaconazole for Histoplasmosis

18+
All Sexes
Minneapolis, MN

The purpose of the study is threefold: 1. Assess the safety and efficacy of a single high-dose intravenous (LAmB 10mg/kg) compared to the SOC daily dosing (3mg/kg) of the same medication for induction therapy in moderate to severe histoplasmosis. 2. Assess the safety and efficacy of oral posaconazole 300mg delayed-release tablets three times daily for two days then once daily for consolidation therapy compared to SOC oral itraconazole 200 mg capsules three times daily for three days then twice daily in moderate to severe histoplasmosis 3. Assess the safety and efficacy of 6 months of consolidation therapy compared to the SOC 12 months of consolidation therapy in persons with HIV on appropriate antiretroviral therapy.

Phase 3
Waitlist Available

University of Minnesota

Nathan Bahr, MD

Image of University of Alberta in Edmonton, Canada.

Fibroscan-Guided Immunosuppression Reduction for Post-Transplant Care

18+
All Sexes
Edmonton, Canada

Following Liver transplantation, recipients remain on life long immunosuppression. Prolonged exposure to immunosuppression is associated with side effects and complications including kidney dysfunction, diabetes, heart disease and cancer risk. Therefore studies are looking at safe ways to reduce or stop immunosuppression. An individual without autoimmune liver disease (these patients are at higher risk of rejection), without history of rejection, with normal blood tests (liver biochemistry, liver function, etc.) can be eligible for minimization of immunosuppression. A recent study showed use of fibroscan (an Ultrasound, which provides information on liver stiffness (diseased liver is hard while a normal liver is soft) and fat content) provides more objective information to help investigators select individuals who will tolerate immunosuppression minimization. Our goal is to see if use of fibroscan allows the investigators to safely minimize immunosuppression in eligible individuals. The secondary aims are to assess benefit on kidney function, heart disease and risk factors for heart disease.

Recruiting
Has No Placebo

University of Alberta

Have you considered Vfend clinical trials?

We made a collection of clinical trials featuring Vfend, we think they might fit your search criteria.
Go to Trials
Image of University of California, San Francisco in San Francisco, United States.

Maraviroc for Primary Graft Dysfunction

18+
All Sexes
San Francisco, CA

Lung transplant recipient survival lags other solid organ recipients, with the main early cause of death being primary graft dysfunction (PGD). PGD occurs in up to 1/3 of all recipients, is driven by the body's innate immune response, and has no known medical therapies for treatment or prevention. Investigators have recently shown that Natural Killer (NK) cells, a key innate immune cell, are critical in causing PGD. Importantly, the investigators found that Maraviroc, an FDA-approved drug that works to inhibit these immune cells, prevented lung injury in mouse models of PGD. The goal of this clinical trial is to learn if Maraviroc works to treat PGD in Lung Transplant patients who are above the age of 18 and have a PGD risk score greater than 50%. The objectives the study hopes to address are: To address the safety and tolerability of Maraviroc. To test a strategy for PGD enrichment in a lung transplant population. To measure the efficacy and biological efficacy of using Maraviroc. To study the biochemical, physiologic, and molecular effects of the drug on the body. This will be a double blind study where patients will either get the Maraviroc drug or a placebo. Researchers will then compare the two groups to address the above objectives. Participants will: Take drug Maraviroc or a placebo every 12 hours for 3 days post surgery. Follow up will occur during the entire length of stay at UCSF, about 16 days, with a single 12 month follow up once released.

Phase 2
Recruiting

University of California, San Francisco

Daniel Calabrese, MD

Image of Kidney Transplant Research in Vancouver, Canada.

Immunosuppressants for Kidney Transplant

18+
All Sexes
Vancouver, Canada

Kidney transplant is often the best treatment for people with kidney failure, but transplanted kidneys don't always last a lifetime. Many transplanted kidneys fail within 12 years, leaving patients needing dialysis or another transplant. One major issue is something called "allosensitization," which happens when the immune system attacks the donated kidney due to foreign markers on the kidney. This makes it harder to match a patient with another donor kidney in the future. To try to prevent this, patients are given immunosuppressants (drugs that weaken the immune system) after a transplant to stop the immune system from attacking the new kidney. However, after a kidney transplant fails and patients return to dialysis, there's no clear evidence that continuing immunosuppressants helps prevent allosensitization. Plus, these drugs have serious risks, including infections, heart disease, and even cancer. The PART study is a pilot study designed to explore whether continuing immunosuppression after a failed transplant for two years (instead of stopping after six months) can lower the risk of allosensitization and whether it is safe to do so. This pilot will also gather data that will be used for a larger trial in the future. The study will be done at 12 different research centers, and around 96 patients will be enrolled in the pilot trial. The ultimate goal is to better understand if continuing immunosuppressants after transplant failure can make a difference, and whether it's safe enough to proceed to a larger, more definitive trial.

Waitlist Available
Has No Placebo

Kidney Transplant Research

Image of Weill Cornell Medical College in New York, United States.

Luspatercept for Clonal Cytopenia

18+
All Sexes
New York, NY

The purpose of this clinical trial is to test how well the drug luspatercept works in improving low blood cell counts in people with clonal cytopenias of uncertain significance (CCUS). The main questions the study seeks to answer include: * How many patients experience improvements in their low blood counts (red cells, platelets, or white cells) within 24 weeks, based on specific criteria for blood conditions like myelodysplastic syndromes (MDS)? * How long these improvements last before the condition worsens or changes. * The percentage of participants showing improvements at 12, 24, and 48 weeks. * How long it takes for the condition to progress to more severe diseases like myeloid disorders. * How long red blood cell responses last and how quickly these responses are seen. * The average change in hemoglobin levels over 24 weeks. * How many patients need blood transfusions during the study and how soon transfusions are required. * Changes in participants' well-being and energy levels based on a standardized questionnaire. * Monitoring for any side effects, including progression to MDS or leukemia, heart-related issues, or sudden increases in hemoglobin. Participants will: * Receive luspatercept as an injection every three weeks. * Visit the clinic every three weeks for treatment and monitoring.

Phase 2
Recruiting

Weill Cornell Medical College

Pinkal Desai, MD

Bristol-Myers Squibb

Have you considered Vfend clinical trials?

We made a collection of clinical trials featuring Vfend, we think they might fit your search criteria.
Go to Trials
Image of University of California, Los Angeles (Site #: 71123) in Los Angeles, United States.

Belumosudil for Lung Transplant

Any Age
All Sexes
Los Angeles, CA

The purpose of this study is to see if taking the study drug, Belumosudil, for 52 weeks in addition to your usual care and medication, will prevent Chronic Lung Allograft Dysfunction (CLAD) in participants who have a lung biopsy that shows evidence of rejection or inflammation to the transplanted lung(s). For this study, biopsies that show evidence of Acute Rejection (AR), Lymphocytic Bronchiolitis (LB), Organizing Pneumonia (OP) or Acute Lung Injury (ALI) are referred to as "Qualifying Biopsies"; patients who had evidence of one or more of these conditions on a recent biopsy are eligible for enrollment in this study. Belumosudil is an investigational drug that blocks a molecule in the body that reduces inflammation and scarring and may play a role in the development and progression of CLAD. Belumosudil is a drug approved by the FDA to treat adults and children 12 years and older with chronic graft-versus-host disease (cGVHD), a condition with some similarities to CLAD. The primary objective it to determine the efficacy of treatment with Belumosudil + maintenance immunosuppression (IS) versus placebo + maintenance IS on preventing the subsequent development of probable or definite CLAD, lung retransplant, or death.

Phase 2
Recruiting

University of California, Los Angeles (Site #: 71123) (+13 Sites)

Scott M. Palmer, M.D., M.H.S.

Image of NYU Langone Health in New York, United States.

New Protocol for Lung Transplants

18+
All Sexes
New York, NY

The study team developed an uncontrolled donation after circulatory death (uDCD) protocol that preserves lungs for just over 3 hours after death using positive end expiratory pressure (PEEP) and supplemental oxygen. The study will assess lung uDCD program safety by continuous review of operations/clinical records from each case activation and transplantation. Attrition outcomes include rates of initial and continued lung preservation, donation authorization, lung recovery, passing ex-vivo lung perfusion (EVLP) performance testing, and lung transplantation. Planned viability assessments also include macroscopic determination, radiology (X-ray), and fiber optic bronchoscopy before initiating EVLP. We expect \~50% of lungs assessed with EVLP will be transplanted to meet sustainability targets. Safety outcomes include the primary outcome, primary graft dysfunction (PGD) grade III at 72 hours, and secondarily survival one year after transplantation.

Recruiting
Has No Placebo

NYU Langone Health

Stephen Wall, MD

Have you considered Vfend clinical trials?

We made a collection of clinical trials featuring Vfend, we think they might fit your search criteria.
Go to Trials